Effects of Dietary Anticarcinogens and Nonsteroidal Anti-inflammatory Drugs on Rat Gastrointestinal UDP-Glucuronosyltransferases

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 843-849

  Van Der Logt, Elise M J ^a   Roelof, Hennie M J ^a   Van Lieshout, Esther M M ^a   Nagengast, Fokko M ^a   Peters, Wilbert H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticarcinogens; Chemoprevention; NSAIDs; UDP glucuronosyltransferases; Wistar rat

Indexed keywords

3 INDOLEMETHANOL; 4 NITROPHENOL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BETA CAROTENE; GLUCURONOSYLTRANSFERASE; HYMECROMONE; IBUPROFEN; INDOMETACIN; LIMONENE; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PHENETHYL ISOTHIOCYANATE; PIROXICAM; SULFORAPHANE; SULINDAC;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DETOXIFICATION; DIETARY INTAKE; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; LARGE INTESTINE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SMALL INTESTINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; DIETARY SUPPLEMENTS; ENZYME INDUCTION; GLUCURONOSYLTRANSFERASE; HYMECROMONE; INTESTINE, SMALL; LIVER; NITROPHENOLS; RATS;

EID: 2442497423     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Greenwald P, Clifford CK and Milner JA: Diet and cancer prevention. Eur J Cancer 37: 948-965, 2001.
2. Terry P, Terry JB and Wolk A: Fruit and vegetable consumption in the prevention of cancer: an update. J Intern Med 250: 280-290, 2001.
3. Ames BN: Dietary carcinogens and anti-carcinogens. J Toxicol Clin Toxicol 22: 291-301, 1984.
4. Food, Nutrition and the Prevention of Cancer: A Global Perspective. World Cancer Research Fund, 1997.
5. Tsuda H, Uehara N, Iwahori Y, Asamoto M, Iigo M, Nagao M, Matsumoto K, Ito M and Hirono I: Chemopreventive effects of beta-carotene, alpha-tocopherol and five naturally occurring antioxidants on initiation of hepatocarcinogenesis by 2-amino-3-methylimidazo[4,5-f]quinoline in the rat. Jpn J Cancer Res 85: 1214-1219, 1994
6. Alabaster O, Tang Z, Frost A and Shivapurkar N: Effect of beta-carotene and wheat bran fiber on colonic aberrant crypt and tumour formation in rats exposed to azoxymethane and high dietary fat. Carcinogenesis 16: 127-132, 1995.
7. Azuine MA, Goswami UC, Kayal JJ and Bhide SV: Antimutagenic and anticarcinogenic effects of carotenoids and dietary palm oil. Nutr Cancer 17: 287-295, 1992.
8. Knekt P, Aromaa A, Maatela J, Aaran RK, Nikkari T, Hakama M, Hakulinen T, Peto R, Saxen E and Teppo L: Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 127: 28-41, 1988.
9. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N and Goebell H: Colorectal adenomas and diet: a case-control study. Colorectal Adenoma Study Group. Dig Dis Sci 46: 86-95, 2001.
10. Terry P, Lagergren J, Ye W, Nyren O and Wolk A: Antioxidants and cancers of the oesophagus and gastric cardia. Int J Cancer 87: 750-754, 2000.
11. Malila N, Virtamo J, Virtanen M, Pietinen P, Albanes D and Teppo L: Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers. Eur J Clin Nutr 56: 615-621, 2002.
12. Stoner GD, Kresty LA, Carlton PS, Siglin JC and Morse MA: Isothiocyanates and freeze-dried strawberries as inhibitors of oesophageal cancer. Toxicol Sci 52: 95-100, 1999.
13. Chung FL, Conaway CC, Rao CV and Reddy BS: Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21: 2287-2291, 2000.
14. Wattenberg LW and Loub WD: Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 38: 1410-1413, 1978.
15. Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K and Kelloff GJ: Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5: 355-360, 1996.
16. Stoner G, Casto B, Ralston S, Roebuck B, Pereira C and Bailey G: Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol. Carcinogenesis 23: 265-272, 2002.
17. Manson MM, Hudson EA, Ball HW, Barrett MC, Clark HL, Judah DJ, Verschoyle RD and Neal GE: Chemoprevention of aflatoxin B1-induced carcinogenesis by indole-3-carbinol in rat liver-predicting the outcome using early biomarkers. Carcinogenesis 19: 1829-1836, 1998.
18. Uedo N, Tatsuta M, Iishi H, Baba M, Sakai N, Yano H and Otani T: Inhibition by D-limonene of gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Cancer Lett 137: 131-136, 1999.
19. Kawamori T, Tanaka T, Hirose Y, Ohnishi M and Mori H: Inhibitory effects of d-limonene on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Carcinogenesis 17: 369-372, 1996
20. Kaji I, Tatsuta M, Iishi H, Baba M, Inoue A and Kasugai H: Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(ras) plasma membrane association. Int J Cancer 93: 441-444, 2001.
21. Posner GH, Cho CG, Green JV, Zhang Y and Talalay P: Design and synthesis of bifunctional isothiocyanate analogs of sulforaphane: correlation between structure and potency as inducers of anticarcinogenic detoxification enzymes. J Med Chem 37: 170-176, 1994.
22. Nishikawa A, Tanakamura Z, Furukawa F, Lee IS, Kasahara K, Ikezaki S and Takahashi M: Chemopreventive activity of oltipraz against induction of glandular stomach carcinogenesis in rats by N-methyl-N′ -nitro-N-nitrosoguanidine. Carcinogenesis 19: 365-368, 1998.
23. Rao CV, Rivenson A, Katiwalla M, Kelloff GJ and Reddy BS: Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 53: 2502-2506, 1993.
24. Primiano T, Egner PA, Sutter TR, Kelloff GJ, Roebuck BD and Kensler TW: Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res 55: 4319-4324, 1995.
25. Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Qian GS, Kuang SY, Li YF, Fang X, Yu LY, De Flora S, Jacobson LP, Zarba A, Egner PA, He X, Wang JS, Chen B, Enger CL, Davidson NE, Gordon GB, Gorman MB, Prochaska HJ, Groopman JD, Munoz A and Kensler TW: Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. J Cell Biochem Suppl 28-29: 166-173, 1997.
26. Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, Qian GS, Kuang SY, Zarba A, Egner PA, Jacobson LP, Munoz A, Helzlsouer KJ, Groopman JD and Kensler TW: Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 91: 347-354, 1999.
27. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
28. Roy HK, Karolski WJ and Ratashak A: Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer 92: 609-615, 2001.
29. Tanaka T, Suzui M, Kojima T, Okamoto K, Wang A and Mori H: Chemoprevention of the naturally occurring carcinogen 1-hydroxyanthraquinone-induced carcinogenesis by the nonsteroidal anti-inflammatory drug indomethacin in rats. Cancer Detect Prev 19: 418-425, 1995.
30. Tanaka T, Kojima T, Okumura A, Sugie S and Mori H: Inhibitory effect of the non-steroidal anti-inflammatory drugs, indomethacin and piroxicam on 2-acetylaminofluorene-induced hepatocarcinogenesis in male ACI/N rats. Cancer Lett 68: 111-118, 1993.
31. Jalbert G and Castonguay A: Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 66: 21-28, 1992.
32. Wargovich MJ, Jimenez A, McKee K, Steele VE, Velasco M, Woods J, Price R, Gray K and Kelloff GJ: Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21: 1149-1155, 2000.
33. Ritland SR and Gendler SJ: Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 20: 51-58, 1999.
34. Denda A, Tang Q, Endoh T, Tsujiuchi T, Horiguchi K, Noguchi O, Mizumoto Y, Nakae D and Konishi Y: Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis 15: 1279-1283, 1994.
35. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G and Schilsky R: A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890, 2003
36. Kishimoto Y, Yashima K, Morisawa T, Ohishi T, Marumoto A, Sano A, Idobe-Fujii Y, Miura N, Shiota G, Murawaki Y and Hasegawa J: Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane. J Cancer Res Clin Oncol 128: 589-595, 2002.
37. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS and Burgart LJ: Chemoprevention of oesophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's oesophagus. Gastroenterology 122: 1101-1112, 2002.
38. Cruz-Correa M, Hylind LM, Romans KE, Booker SV and Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122: 641-645, 2002.
39. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ and Hamilton SR: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059, 2002.
40. Tukey RH and Strassburg CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40: 581-616, 2000.
41. Hayes JD and Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600, 1995.
42. King CD, Rios GR, Green MD and Tephly TR: UDP-glucuronosyltransferases. Curr Drug Metab 1: 143-161, 2000
43. Peters WH, Kock L, Nagengast FM and Kremers PG: Biotransformation enzymes in human intestine: critical low levels in the colon? Gut 32: 408-412, 1991.
44. van Lieshout EM, Peters WH and Jansen JB: Effect of oltipraz, alpha-tocopherol, beta-carotene and phenethylisothiocyanate on rat oesophageal, gastric, colonic and hepatic glutathione, glutathione S-transferase and peroxidase. Carcinogenesis 17: 1439-1445, 1996.
45. van Lieshout EM, Tiemessen DM, Peters WH and Jansen JB: Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract. Carcinogenesis 18: 485-490, 1997.
46. van Lieshout EM, Posner GH, Woodard BT and Peters WH: Effects of the sulforaphane analogue compound 30, indole-3-carbinol, D-limonene or relafen on glutathione S-transferases and glutathione peroxidase of the rat digestive tract. Biochim Biophys Acta 1379: 325-336, 1998
47. Lowry OH, Rosebrough NJ, Farr AL and Randal RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
48. Peters WH, Jansen PL and Nauta H: The molecular weights of UDP-glucuronyltransferase determined with radiation-inactivation analysis. A molecular model of bilirubin UDP-glucuronyltransferase. J Biol Chem 259: 11701-11705, 1984.
49. Lamb JG and Franklin MR: Early events in the induction of rat hepatic UDP-glucuronosyltransferases, glutathione S-transferase, and microsomal epoxide hydrolase by 1,7-phenanthroline: comparison with oltipraz, tert-butyl-4-hydroxyanisole, and tertbutylhydroquinone. Drug Metab Dispos 28: 1018-1023, 2000.
50. Guo Z, Smith TJ, Wang E, Sadrieh N, Ma Q, Thomas PE and Yang CS: Effects of phenethyl isothiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. Carcinogenesis 13: 2205-2210, 1992.
51. Vargas M, Lamb JG and Franklin MR: Phase II-selective induction of hepatic drug-metabolizing enzymes by oltipraz-5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione-, 1,7-phenanthroline, and 2,2′-dipyridyl in rats is not accompanied by induction of intestinal enzymes. Drug Metab Dispos 26: 91-97, 1998.
52. Astorg P, Gradelet S, Leclerc J, Canivenc MC and Siess MH: Effects of beta-carotene and canthaxanthin on liver xenobiotic-metabolizing enzymes in the rat. Food Chem Toxicol 32: 735-742, 1994.
53. Basten GP, Bao Y and Williamson G: Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. Carcinogenesis 23: 1399-1404, 2002.
54. Wong BK, Fei P and Kong AN: Differential induction of UDP-glucuronosyltransferase activity and gene expression in rat liver. Pharm Res 12: 1105-1108, 1995.
55. Elegbede JA, Maltzman TH, Elson CE and Gould MN: Effects of anticarcinogenic monoterpenes on phase II hepatic metabolizing enzymes. Carcinogenesis 14: 1221-1223, 1993.
56. Falzon M, Whiting PH, Ewen SW, Milton AS and Burke MD: Comparative effects of indomethacin on hepatic enzymes and histology and on serum indices of liver and kidney function in the rat. Br J Exp Pathol 66: 527-534, 1985.
57. Grams B, Harms A, Braun S, Strassburg CP, Manns MP and Obermayer-Straub P: Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. Arch Biochem Biophys 377: 255-265, 2000.
58. Shelby MK, Cherrington NJ, Vansell NR and Klaassen CD: Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31: 326-333, 2003.
59. Ritter JK: Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129: 171-193, 2000.
60. Bock KW, Lilienblum W and von Bahr C: Studies of UDP-glucuronyltransferase activities in human liver microsomes. Drug Metab Dispos 12: 93-97, 1984.
61. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M and Biswal S: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196-5203, 2002.